VIENNA – The survival benefit shown by nivolumab in the phase III CheckMate 025 trial may offer hope of even longer survival benefits in advanced ki
Field of Interest: Oncology

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness